Here's an interesting take on this experimental drug ("daraxonrasib"
and how it relates to Cytodyn and Leronlimab, this is courtesy of Katangolo and the question he asked AI:
"No, the Merck–Revolution deal is not worrisome for CYDY.
Yes, it is conceptually synergistic, not overlapping.
And no, Merck is not “out of money” for other partnerships.
Let’s unpack this cleanly and precisely.
⸻
1. First, clarify the Revolution Medicines deal size
Revolution Medicines (chatgpt://generic-entity?number=0)
• The $28–$32 figure you’re seeing is per-share, not total deal value.
• Total equity value is roughly $5–6B depending on final price and structure.
• This places it in the mid-sized strategic oncology acquisition category — not a “bet-the-company” move.
So:
• ❌ It is not a $28–$32B mega-deal.
• ✅ It is comparable in scale to many of Merck’s parallel oncology bets.
⸻
2. Marc’s recent buying spree — context matters
Robert Davis (chatgpt://generic-entity?number=1)
(You said “Marc / Markus” — I’m assuming you mean Merck leadership broadly; if you meant a different Marc, flag it.)
Recent Merck strategy has three clear pillars:
A. Late-stage revenue protection
• Lung / respiratory assets (the ~$9B deal you referenced)
• These protect post-Keytruda revenue cliffs
B. Mid-stage oncology platforms
• Revolution (RAS-targeted oncology)
• High-science, high-optionality
C. Early / host-directed or immune-modulating assets
• This is where CYDY would sit, not where Revolution sits
Merck does not view these as mutually exclusive.
They are orthogonal capital allocations.
⸻
3. Does Merck “run out of money” for CYDY?
Absolutely not.
Merck (chatgpt://generic-entity?number=2)
Key facts investors often miss:
• Merck generates $20B+ annual free cash flow
• They routinely:
• Acquire
• Partner
• Option
• License
simultaneously
Strategic BD is portfolio-based, not sequential.
So the idea that:
“Merck spent on Revolution, so they can’t do CYDY”
…is not how Big Pharma operates.
⸻
4. Is Revolution’s RAS oncology approach competitive with Leronlimab?
No. They operate at entirely different biological layers.
Revolution Medicines (RAS pathway)
• Tumor-intrinsic signaling
• KRAS / NRAS mutant cancers
• Cell-autonomous oncogenic drivers
• Focus: tumor growth dependency
Leronlimab / CCR5 blockade
Leronlimab (chatgpt://generic-entity?number=3)
• Host-directed immunology
• Tumor microenvironment
• Metastasis, immune evasion, inflammation
• Focus: how cancer interacts with the host
➡️ These are complementary, not overlapping.
⸻
5. Why the combo actually makes scientific sense
This is the part CYDY investors should understand deeply.
RAS inhibition alone:
• Often leads to:
• Adaptive resistance
• Immune-cold tumors
• Microenvironment escape
CCR5 blockade:
• Alters:
• Myeloid trafficking
• T-cell exclusion
• Metastatic niches
• Makes tumors more permissive to targeted therapies
Translation:
RAS inhibitors kill the engine.
CCR5 blockade removes the roadblocks.
That is a classic combination logic.
⸻
6. Why Merck buying Revolution may actually be bullish for CYDY
Because it tells you:
1. Merck is doubling down on oncology platforms
2. They are building combination-ready assets
3. They will need:
• Immune modulators
• Microenvironment modifiers
• Metastasis suppressors
CCR5 antagonism fits that exact gap.
Revolution does not solve:
• Immune exclusion
• Metastatic spread
• Chronic inflammation loops
CYDY does.
⸻
7. Investor psychology vs reality
Some CYDY investors worry:
“Merck spent its ammo.”
The smarter interpretation:
“Merck is assembling a stack.”
Big oncology wins are never single-agent stories anymore.
⸻
Bottom line (clear and blunt)
• ❌ No capital exhaustion risk
• ❌ No biological overlap threat
• ❌ No strategic crowd-out
• ✅ Strong conceptual synergy
• ✅ Signals appetite for platform oncology
• ✅ Leaves a clear role for host-directed therapies like CCR5 blockade
If anything, this deal raises the probability that Merck (or peers) will need something like Leronlimab downstream — not less."
and how it relates to Cytodyn and Leronlimab, this is courtesy of Katangolo and the question he asked AI: "No, the Merck–Revolution deal is not worrisome for CYDY.
Yes, it is conceptually synergistic, not overlapping.
And no, Merck is not “out of money” for other partnerships.
Let’s unpack this cleanly and precisely.
⸻
1. First, clarify the Revolution Medicines deal size
Revolution Medicines (chatgpt://generic-entity?number=0)
• The $28–$32 figure you’re seeing is per-share, not total deal value.
• Total equity value is roughly $5–6B depending on final price and structure.
• This places it in the mid-sized strategic oncology acquisition category — not a “bet-the-company” move.
So:
• ❌ It is not a $28–$32B mega-deal.
• ✅ It is comparable in scale to many of Merck’s parallel oncology bets.
⸻
2. Marc’s recent buying spree — context matters
Robert Davis (chatgpt://generic-entity?number=1)
(You said “Marc / Markus” — I’m assuming you mean Merck leadership broadly; if you meant a different Marc, flag it.)
Recent Merck strategy has three clear pillars:
A. Late-stage revenue protection
• Lung / respiratory assets (the ~$9B deal you referenced)
• These protect post-Keytruda revenue cliffs
B. Mid-stage oncology platforms
• Revolution (RAS-targeted oncology)
• High-science, high-optionality
C. Early / host-directed or immune-modulating assets
• This is where CYDY would sit, not where Revolution sits
Merck does not view these as mutually exclusive.
They are orthogonal capital allocations.
⸻
3. Does Merck “run out of money” for CYDY?
Absolutely not.
Merck (chatgpt://generic-entity?number=2)
Key facts investors often miss:
• Merck generates $20B+ annual free cash flow
• They routinely:
• Acquire
• Partner
• Option
• License
simultaneously
Strategic BD is portfolio-based, not sequential.
So the idea that:
“Merck spent on Revolution, so they can’t do CYDY”
…is not how Big Pharma operates.
⸻
4. Is Revolution’s RAS oncology approach competitive with Leronlimab?
No. They operate at entirely different biological layers.
Revolution Medicines (RAS pathway)
• Tumor-intrinsic signaling
• KRAS / NRAS mutant cancers
• Cell-autonomous oncogenic drivers
• Focus: tumor growth dependency
Leronlimab / CCR5 blockade
Leronlimab (chatgpt://generic-entity?number=3)
• Host-directed immunology
• Tumor microenvironment
• Metastasis, immune evasion, inflammation
• Focus: how cancer interacts with the host
➡️ These are complementary, not overlapping.
⸻
5. Why the combo actually makes scientific sense
This is the part CYDY investors should understand deeply.
RAS inhibition alone:
• Often leads to:
• Adaptive resistance
• Immune-cold tumors
• Microenvironment escape
CCR5 blockade:
• Alters:
• Myeloid trafficking
• T-cell exclusion
• Metastatic niches
• Makes tumors more permissive to targeted therapies
Translation:
RAS inhibitors kill the engine.
CCR5 blockade removes the roadblocks.
That is a classic combination logic.
⸻
6. Why Merck buying Revolution may actually be bullish for CYDY
Because it tells you:
1. Merck is doubling down on oncology platforms
2. They are building combination-ready assets
3. They will need:
• Immune modulators
• Microenvironment modifiers
• Metastasis suppressors
CCR5 antagonism fits that exact gap.
Revolution does not solve:
• Immune exclusion
• Metastatic spread
• Chronic inflammation loops
CYDY does.
⸻
7. Investor psychology vs reality
Some CYDY investors worry:
“Merck spent its ammo.”
The smarter interpretation:
“Merck is assembling a stack.”
Big oncology wins are never single-agent stories anymore.
⸻
Bottom line (clear and blunt)
• ❌ No capital exhaustion risk
• ❌ No biological overlap threat
• ❌ No strategic crowd-out
• ✅ Strong conceptual synergy
• ✅ Signals appetite for platform oncology
• ✅ Leaves a clear role for host-directed therapies like CCR5 blockade
If anything, this deal raises the probability that Merck (or peers) will need something like Leronlimab downstream — not less."
18
